Relay Therapeutics Inc | TalkMarkets | Page 1
No data available
No data available

People who follow this stock (15)

View All

Latest Posts

About This Stock More About This Stock
Clinical-Stage BioTech Drug Stocks Portfolio Went Down 9% Last Week
Article By: Lorimer Wilson
Tuesday, April 23, 2024 12:57 PM EDT
A look at the 10 clinical-stage AI-powered and psychedelic compound-based small-cap drug discovery companies in our Clinical-Stage BioTech Drug Stocks Portfolio, their stock performances last week and MTD, and their areas of focus.
In this article: ATAI, MNMD, ABCL, RLAY, GHRS, ABSI, RXRX
Read
Micro/Small Cap Companies Using AI In Drug Discovery Up 35% In November
Article By: Lorimer Wilson
Wednesday, December 6, 2023 1:53 PM EDT
The AI method is up to 250 times more efficient than the traditional method of drug discovery. reducing timelines for drug discovery, increasing accuracy of efficacy and safety predictions.
In this article: EXAI, SDGR, ABCL, RLAY, RXRX, BTAI
Read
Looking To Invest In Artificial Intelligence? Consider Evogene And Its Five Subsidiaries
Article By: Alan Sumler
Thursday, April 27, 2023 9:33 AM EDT
Evogene employs an AI platform for decoding plant phenotypes and microbial genomes. The set-up may present a long-tern investment strategy.
In this article: EVGN Also: CTVA, BAYRY, DNA, SDGR, RLAY
Read
Evogene Offers An Excellent Risk/Reward Ratio
Article By: Shareholders Unite
Wednesday, March 22, 2023 9:35 AM EDT
We think the company’s main CPB computational engine has the potential to be an extraordinary value creation engine.
In this article: EVGN Also: SDGR, EXAI, RLAY, DNA, CTVA, BAYRY
Read
Gain Therapeutics: Reasons For Optimism
Article By: Kate Hayden
Wednesday, August 10, 2022 9:00 AM EDT
In biotechnology, potential rules. And in Gain's case, the potential to not just treat but functionally cure at least some forms of Parkinson's Disease is strong enough to weather early-stage challenges.
In this article: GANX Also: SDGR, RLAY, EXAI
Read
All Posts

Latest Tweets for $RLAY

No tweets yet!

PARTNER HEADLINES